A role for lipid mediators in acute myeloid leukemia
A Loew, T Köhnke, E Rehbeil, A Pietzner… - International journal of …, 2019 - mdpi.com
In spite of therapeutic improvements in the treatment of different hematologic malignancies,
the prognosis of acute myeloid leukemia (AML) treated solely with conventional induction …
the prognosis of acute myeloid leukemia (AML) treated solely with conventional induction …
Impaired NK cells and increased T regulatory cell numbers during cytotoxic maintenance therapy in AML
FS Lichtenegger, R Lorenz, K Gellhaus… - Leukemia research, 2014 - Elsevier
Cyclic cytotoxic maintenance therapy can be applied to patients with AML in post-remission.
We studied the immune status of AML patients in complete remission and the effect of …
We studied the immune status of AML patients in complete remission and the effect of …
The more, the better:“do the right thing” for natural killer immunotherapy in acute myeloid leukemia
S Parisi, M Lecciso, D Ocadlikova… - Frontiers in …, 2017 - frontiersin.org
Natural killer (NK) cells are circulating CD3− lymphocytes, which express CD56 or CD16
and an array of inhibitory receptors, called killer-immunoglobulin-like receptors (KIRs) …
and an array of inhibitory receptors, called killer-immunoglobulin-like receptors (KIRs) …
Updates in immunotherapy for acute myeloid leukemia
E Nagler, MF Xavier, N Frey - Translational Cancer Research, 2017 - tcr.amegroups.org
Acute myeloid leukemia (AML) is the most common acute leukemia among adults with an
overall poor prognosis. For 40 years there has been minimal improvement in treatment …
overall poor prognosis. For 40 years there has been minimal improvement in treatment …
急性髓系白血病免疫治疗的研究进展与展望.
张王刚， 白菊 - Journal of Xi'an Jiaotong University (Medical …, 2015 - search.ebscohost.com
摘要大多数急性髓系白血病!= 24) 5>/5?@ A.? 54B5> A= &C; D" 患者化疗诱导缓解后不可避免
地面临复发'异基因造血干细胞移植作为C; D 最有效的治疗& 通过免疫介导的移植物抗白血病 …
地面临复发'异基因造血干细胞移植作为C; D 最有效的治疗& 通过免疫介导的移植物抗白血病 …
Новые маркеры прогрессирования хронического миелолейкоза
ВА Мисюрин, АВ Мисюрин, ЛА Кесаева… - Клиническая …, 2014 - cyberleninka.ru
Хронический миелоидный лейкоз (ХМЛ) отличается от Ph-негативных хронических
миелопролиферативных заболеваний (хМПЗ) относительно более ранней …
миелопролиферативных заболеваний (хМПЗ) относительно более ранней …
Assessment of the presence and anti-tumor potential of tumor-infiltrating lymphocytes in patients with acute myeloid leukemia
L Wei, Z Wang, Z Zhang, Y Li, S Fan… - Cancer Management …, 2019 - Taylor & Francis
Purpose: Assessing the possibility of finding tumor-infiltrating lymphocytes (TIL) in bone
marrow of acute myeloid leukemia (AML) patients and evaluating the anti-tumor activity of …
marrow of acute myeloid leukemia (AML) patients and evaluating the anti-tumor activity of …
RNA and protein expression of herpesvirus entry mediator (HVEM) is associated with molecular markers, immunity-related pathways and relapse-free survival of …
FS Lichtenegger, I Kondla, M Krempasky… - Cancer Immunology …, 2015 - Springer
Immune checkpoint molecules are highly relevant as potential prognostic markers and
therapeutic targets in malignant diseases. HVEM belongs to the TNF receptor family and …
therapeutic targets in malignant diseases. HVEM belongs to the TNF receptor family and …
[PDF][PDF] T-Zell-Aktivierung als Therapiestrategie bei Patienten mit akuter myeloischer Leukämie
F Lichtenegger - 2023 - edoc.ub.uni-muenchen.de
Die akute myeloische Leukämie (AML) ist eine klonale Erkrankung primitiver
hämatopoetischer Vorläuferzellen. Verursacht wird diese durch vielfältige genetische …
hämatopoetischer Vorläuferzellen. Verursacht wird diese durch vielfältige genetische …